These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36512133)

  • 1. Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?
    Cheung WY; Cameron C; Mitha A; Wills A
    Support Care Cancer; 2022 Dec; 31(1):5. PubMed ID: 36512133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?
    Wills A; Mitha A
    Value Health; 2024 Mar; 27(3):340-346. PubMed ID: 38154595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.
    Avşar TS; Elvidge J; Hawksworth C; Kenny J; Németh B; Callenbach M; Ringkvist J; Dawoud D
    Value Health; 2024 Jul; ():. PubMed ID: 39094693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
    Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manufacturers' views on outcome-based agreements.
    Barjestehvan Waalwijk van Doorn-Khosrovani S; Timmers L; Pisters-van Roy A; Gijzen J; Blijlevens NMA; Bloemendal H
    J Mark Access Health Policy; 2021; 9(1):1993593. PubMed ID: 34745459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study.
    Kim MJ; Kim HJ; Kang D; Ahn HK; Shin SY; Park S; Cho J; Park YH
    J Med Internet Res; 2023 Mar; 25():e43359. PubMed ID: 36951923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generating and using real-world data: A worthwhile uphill battle.
    Verkerk K; Voest EE
    Cell; 2024 Mar; 187(7):1636-1650. PubMed ID: 38552611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
    Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
    BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
    Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
    [No Abstract]   [Full Text] [Related]  

  • 11. Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions.
    Castellanos EH; Wittmershaus BK; Chandwani S
    JCO Clin Cancer Inform; 2024 Jan; 8():e2300046. PubMed ID: 38241599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.
    Merola D; Campbell U; Gautam N; Rubens A; Schneeweiss S; Wang SV; Carrigan G; Chia V; Ovbiosa OE; Pinheiro S; Bruno A; Jiao X; Stewart M; Hendricks-Sturrup R; Rodriguez-Watson C; Khosla S; Zhang Y; Rimawi M; Huang J; Taylor A; Becnel L; McRoy L; Eckert J; Taylor B
    Clin Pharmacol Ther; 2023 Jun; 113(6):1217-1222. PubMed ID: 36408668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When Will Real-World Data Fulfill Its Promise to Provide Timely Insights in Oncology?
    Berger ML; Ganz PA; Zou KH; Greenfield S
    JCO Clin Cancer Inform; 2024 Jun; 8():e2400039. PubMed ID: 38950323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal.
    Pongiglione B; Torbica A; Blommestein H; de Groot S; Ciani O; Walker S; Dams F; Blankart R; Mollenkamp M; Kovács S; Tarricone R; Drummond M
    Int J Technol Assess Health Care; 2021 Apr; 37(1):e62. PubMed ID: 33896433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
    Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
    JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Databases in Real-world Studies Regarding the Diverse Health Care Systems of India, Thailand, and Taiwan: Protocol for a Scoping Review.
    Shau WY; Setia S; Shinde SP; Santoso H; Furtner D
    JMIR Res Protoc; 2022 Dec; 11(12):e43741. PubMed ID: 36512386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
    Jenei K; Peacock S; Burgess M; Mitton C
    Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective.
    Azoulay L
    Oncologist; 2022 Sep; 27(9):e731-e738. PubMed ID: 35762676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.